Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31115697 | 1.00 | APP (1.00) | APPCYP1A2EGFRKDM4EALDH1A1 | |
| SCHEMBL10167882 | 0.89 | APP (1.00) | APPCYP1A2EGFRNPC1RAB9A | |
| SCHEMBL1104921 | 0.87 | APP (1.00) | APPCYP1A2EGFRNPC1RAB9A | |
| SCHEMBL7004388 | 0.86 | APP (0.76) | APPCYP1A2NPC1LMNARAB9A | |
| SCHEMBL10038463 | 0.86 | APP (0.75) | APPCYP1A2EGFRKDM4EALDH1A1 | |
| SCHEMBL10167883 | 0.86 | APP (0.93) | APPCYP1A2EGFR | |
| SCHEMBL1104925 | 0.85 | APP (0.80) | APPCYP1A2EGFRCA12CA1 | |
| SCHEMBL10167864 | 0.85 | APP (1.00) | APPCYP1A2MAOBNPC1RAB9A | |
| SCHEMBL18932158 | 0.85 | APP (0.74) | APPCYP1A2KDM4EALDH1A1HPGD | |
| Ethoxyresorufin SCHEMBL104497 | 0.85 | APP (1.00) | APPCYP1A2CA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106216-A1 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2004-06-03 | — | — | US | claimed |
| EP-1378751-A2 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | Toyo Boseki Kabushiki Kaisha (JP) | 2004-01-07 | — | — | EP | claimed |
| EP-1083223-A1 | NOVEL IMMORTALIZED HEPATIC CELL LINE ORIGINATING IN HUMANS | Takeda Chemical Industries, Ltd. (JP) | 2001-03-14 | — | — | EP | claimed |
| CN-113293150-B | Mutant enzymes | 牛津大学科技创新有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250113821-A1 | Methods and Compositions for Preserving Tissues and Organs | MASSACHUSETTS GEN HOSPITAL (US) | 2025-04-10 | — | — | US | disclosed |
| US-12239126-B2 | Methods and compositions for preserving tissues and organs | THE GENERAL HOSPITAL CORPORATION (US) | 2025-03-04 | — | — | US | disclosed |
| CN-112513252-B | Method for culturing proliferative hepatocytes | 国家健康科学研究所 | 2024-07-12 | — | — | CN | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023137529-A1 | ANTI-PARASITE COMPOUNDS | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2023-07-27 | — | — | WO | disclosed |
| US-11155790-B2 | Mutant enzymes | OXFORD UNIVERSITY INNOVATION LIMITED | 2021-10-26 | — | — | US | disclosed |
| CN-113293150-A | Mutant enzymes | 牛津大学科技创新有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-6394812-B1 | LIVER CELL CULTURE | ORGANOGENESIS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1200110-A1 | IN VIVO INDUCTION FOR ENHANCED FUNCTION OF ISOLATED HEPATOCYTES | ORGANOGENESIS INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6376753-B1 | ISOLATED DNA; POLLUTION CONTROL; ADJUST SENSITIVITY TO PLANT HERBICIDES, PESTICIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2002-04-23 | — | — | US | disclosed |
| US-6335428-B1 | Agents that bind to and inhibit human cytochrome P450 1A2 | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-01-01 | — | — | US | disclosed |
| EP-1083223-A1 | NOVEL IMMORTALIZED HEPATIC CELL LINE ORIGINATING IN HUMANS | Takeda Chemical Industries, Ltd. (JP) | 2001-03-14 | — | — | EP | disclosed |
| WO-2001007069-A1 | IN VIVO INDUCTION FOR ENHANCED FUNCTION OF ISOLATED HEPATOCYTES | ORGANOGENESIS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000004864-A2 | AGENTS THAT BIND TO AND INHIBIT HUMAN CYTOCHROME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-02-03 | — | — | WO | disclosed |
| US-5891696-A | CAN BE STORED AT A TEMPERATURE LESS THAN 8.DEGREE. C. FOR AT LEAST TWO WEEKS AND IS ABLE TO OXIDIZE A DRUG AFTER STORAGE | PANVERA CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998021312-A1 | HUMAN HEPATOCYTES IN THREE-DIMENSIONAL SUPPORT SYSTEMS | RPMS TECHNOLOGY LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | APP 3721/4885CYP1A2 2469/4885EGFR 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.